Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015
Executive Summary
Teva's expansion of its branded drug business will focus on central nervous system therapies, with one of its first regulatory submissions, an NDA for a 40 mg/day dose of multiple sclerosis treatment Copaxone,slated for 2009
You may also be interested in...
Generic Plavix Will Slow U.S. Pharmaceutical Sales Growth In 2006 – IMS
The launch of generic Plavix (clopidogrel) could reduce overall pharmaceutical sales growth for 2006 by nearly one percent, IMS Health VP-Industry Relations Doug Long suggested
Teva Phase IV Study For Parkinson’s Drug Azilect Looks Into Melanoma Risk
Teva will conduct a postmarketing study of its Parkinson's disease drug Azilect (rasagiline) to investigate the risk of melanoma
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal